

State of Oklahoma SoonerCare Sarclisa[®] (Isatuximab-irfc) Prior Authorization Form

Member Name:	Date of Birth:		
	Drug Inform	nation	
☐ Physician billing (HCPCS code	:) 🗖 ,	Pharmacy billing (NDC:	
Start Date (or date of next dose):_	Dose:	Regimen:	
	Billing Provider I	nformation	
Provider NPI:	Provider Name:		
Provider Phone:	Provider Fax:		
	Prescriber Info	ormation	
Prescriber NPI:	NPI:Prescriber Name:		
Prescriber Phone:	_ Prescriber Fax:	Specialty:	
	Criteria	a j	
3. Will isatuximab be used in combine4. If diagnosis is NOT relapsed or re	include lenalidomide an nation with pomalidomid fractory multiple myelor	No ad a proteasome inhibitor? YesNo e and dexamethasone? YesNo ma, please indicate diagnosis:	
For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence 3. Has member experienced any ad If yes, please specify adverse reaction Additional Information:	verse drug reactions rel ns:	ated to isatuximab therapy? Yes No	
Prescriber Signature: I certify that the indicated treatment best of my knowledge.	nt is medically necessa	Date:ary and all information is true and correct to the	

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

form in full will result in processing delays.

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.